S100A2 and benign prostatic hyperplasia: DNA methylation has been postulated as a mechanism underlying the downregulation of S100A2 in prostate cancer, and S100A2 methylation has also been observed in 75% of nonmalignant tissues and 100% of benign prostate hypertrophy cases.